Clinical Trial Update: Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tivozanib in combination with paclitaxel for locally recurrent or metastatic triple negative breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Tivozanib (tivozanib)

Snippet

Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-10-27